{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-26-000024","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.402347+00:00","generated_at":"2026-05-15T07:58:10.582713+00:00","sec_items":["9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Akebia appoints Philip Vickers to board, replacing retiring Steven Gilman","bullets":["Steven Gilman resigned as Class I director effective April 1, 2026; retirement not due to any disagreement.","Philip Vickers elected Class I director effective April 1, 2026; term expires at 2027 annual meeting.","Vickers appointed to Compensation and R&D Committees; receives standard non-employee director compensation.","Vickers granted 214,400 options at $1.41/share on April 1, plus annual cash retainers of $50,000.","Vickers is CEO of Solu Therapeutics; over 30 years biopharma leadership including Shire and Pfizer."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-26-000024","json":"https://secwatch.observer/filing/0001517022-26-000024.json","markdown":"https://secwatch.observer/filing/0001517022-26-000024.md","text":"https://secwatch.observer/filing/0001517022-26-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000024/0001517022-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000024/akba-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:58:10.582713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}